Healthcare Administrator
PNA FISH
*NEW* - GPCC - S. aureus/CNS PNA FISH
*NEW* - Yeast - C. albicans/C. glabrata PNA FISH
GPCC - S. aureus PNA FISH
GPCPC - E. faecalis/OE PNA FISH
Yeast - C. albicans PNA FISH
EVIGENE
*New* KT103 - vanA/B EVIGENE
*New* KT107 - mupA EVIGENE
KT102 - mecA EVIGENE
KT104 - PVL EVIGENE
KT105 - TSST-1 EVIGENE
KT106 - S. aureus EVIGENE
Other Fields
Choose another field below to see how our products can help:
Improve the quality of patient care, hospital resource utilization and reduce costs
Hospitals are under pressure to tackle the rising issue of hospital-associated infections (HAI's), both to improve the quality of patient care and to control costs. In the United States alone, HAI's account for an estimated 2 million infections and $4.5 billion in excess healthcare costs annually.1 The infections can lead to:
◊ Decline in quality of patient care
◊ Increase in length of stay (LOS)
◊ Decrease in bed utilization
◊ Lower revenues per bed
◊ Increase in hospital bed, pharmacy and lab costs
One of the challenges to tackling the problem of HAI's has been that diagnosing the infections can be difficult as conventional laboratory methods can take days and results often arrive too late to influence treatment decisions. The delay in accurate results often forces physicians to treat empirically, whether the patient has a true infection or not, leading to unnecessary, inappropriate or even inadequate therapy.
Opportunity for Healthcare Administrators
AdvanDx's molecular-based diagnostic products provide rapid identification of micro-organisms causing infections. Results from the laboratory are available within hours instead of days and help physicians and pharmacists improve therapy for their patients. By providing the resources and supporting effective implementation of rapid diagnostics, healthcare administrators can help improve overall patient care and control infection related costs.
PNA FISH™ provides rapid identification of bacteria and yeast in positive blood cultures. The accurate results are available in hours instead of days and support appropriate therapy for patients with bloodstream infections. Studies show that implementing PNA FISH can result in:
√ Early appropriate and effective antibiotic therapy
√ Decrease in mortality
◊ Decrease in antimicrobial use3,4
◊ Decrease in hospital length of stay (LOS)3
◊ Significant hospital bed, pharmacy and laboratory cost savings3,4
◊ Development of new therapeutic guidelines2,3,4
EVIGENE™ provides rapid detection of antibiotic resistance and virulence markers in bacteria causing hospital and community acquired infections. The rapid results allow laboratories, physicians, pharmacists and infection control to better coordinate efforts to combat the spread of resistant and virulent bacteria and in turn improve both patient care and overall hospital operations.
Please see individual products for country specific regulatory status
- Centers for Disease Control and Prevention: Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. http://www.cdc.gov/drugresistance/healthcare/default.htm
- Toombs et al. Impact of Peptide Nucleic Acid (PNA) Fluorescence in situ Hybridization (FISH) for Enterococcal blood stream infections. Oral Abstract #131, IDSA 2006 Annual Meeting, Toronto, Canada
- Forrest et al. J Antimicrob Chemother. 2006 Jul;58(1):154-8
- Forrest et al. J. Clin. Microbiol. 2006 44: 3381-3383.